Janux Therapeutics

JANX008 Clin1 colorectal cancer, NSCLC, SCCHN; TROP2-TRACTr RD cancers; JANX009 RD solid tumors

Janux Therapeutics is developing tumor-activated immunotherapies to treat cancer. Current T cell therapies are limited by toxicity and efficacy, particularly for treating solid tumors. Using their platform masking technology, Janux is creating bispecific molecules that are designed to stimulate the immune system only within the tumor microenvironment, reducing the damage to a patient’s healthy tissue. As the molecules are modular, several elements of their technology can be swapped, enabling Janux to rapidly develop new drug candidates. Janux’s lead candidate, JANX007 is in clinical trial development for patients with prostate cancer.